Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia

Blood Adv (2019) 3 (13): 1926–1929.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals